Product Reports Resources Pricing Login Book a demo

Halda Therapeutics

Biotech & Life Sciences · New Haven, United States · Founded 2018

Halda is a biotechnology company focused on developing a new class of precision medicines known as RIPTAC therapeutics to combat cancer. These innovative drugs work by holding two proteins together: one that is tumor-specific and another that performs an essential function, resulting in the selective killing of cancer cells. Halda operates in the biotechnology and pharmaceutical market, primarily serving patients and healthcare providers in the oncology sector. The company's business model revolves around the research, development, and commercialization of these novel therapeutics. Revenue is generated through the sale of these drugs, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. Halda's leadership team, including CFO Scott Phillips, brings extensive experience in finance and biotech, ensuring robust financial management and strategic growth. Keywords: RIPTAC therapeutics, precision medicine, cancer treatment, biotechnology, oncology, protein interaction, tumor-specific, drug development, healthcare, pharmaceutical.

Investors

21 investors on Halda Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 10 investors entered at this stage
Frazier Life Sciences
Access Industries
Canaan
Connecticut Innovations
Taiho Pharma
Vida Ventures
RA Capital Management
Elm Street Ventures
Boxer Capital
Deep Track Capital
Series B+ 11 investors entered at this stage
Taiho Pharma
RA Capital Management
Deep Track Capital
Frazier Life Sciences
Access Industries
Yale University
Elm Street Ventures
Connecticut Innovations
Vida Ventures
Canaan
Boxer Capital

Global footprint

Where Halda Therapeutics has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
7.1K monthly visits
across markets
🇺🇸 United States98.6%
🇳🇱 Netherlands1.4%
Top 2 markets shown

Talent graph

The shape of Halda Therapeutics's talent

Dealroom maps Halda Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

2 team members profilednamed & role-tagged by Dealroom
40 employeestotal headcount
1 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Halda Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$246k patent portfolio · 14 active families

Estimated portfolio value
$246k
<0.01% of valuation · 569.5× smaller than top peer Exelixis ($140M)
14 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Halda Therapeutics

An AI-synthesized read of the highest-engagement posts about Halda Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Halda Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.